Expanding the Overseas Business Base Through Acquisitions and Making Companies Subsidiaries
First written in FY2022-Q2. 4 of 6 entries say "Advanced", first in FY2023-Q1. Latest entry: FY2024-Q2.
The whole theme swung hardest in 2020: 2 of 9 companies on the "Worse" side.
13 other companies' latest entry also says "Advanced".
- FY2024-Q2AdvancedAnnual report
「This resulted from cash outflows of ¥2,611 million for the acquisition of additional shares in SciMed (Asia) Pte Ltd from non-controlling interests during the six-month period.」
The company acquired additional shares in SciMed, which had already become a subsidiary, in a transaction that increased its ownership interest in the overseas sales platform. - FY2023-Q3AdvancedAnnual report
「Goodwill increased by ¥8,153 million due to the impact of the weaker yen and the acquisitions of M-M France SASU and Laurypath SASU, among other factors.」
The company acquired M-M France SASU and Laurypath SASU, and the increase in goodwill has been reflected in the consolidated financial position. It also recorded ¥1,754 million in cash outflows for the acquisition of shares in subsidiaries involving a change in the scope of consolidation. - FY2023-Q2AdvancedAnnual report
「This was because cash outflows for the acquisition of shares in a subsidiary involving a change in the scope of consolidation amounted to ¥1,798 million.」
The company recorded the acquisition of shares in a subsidiary involving a change in the scope of consolidation as an investing outflow during the six-month period. - FY2023-Q1AdvancedAnnual report
「This was mainly because cash outflows for the acquisition of shares in subsidiaries involving a change in the scope of consolidation amounted to ¥1,889 million.」
The company recorded the acquisition of shares in a subsidiary involving a change in the scope of consolidation as an investing cash outflow during the quarter. - FY2022-Q3RestatedAnnual report
「In the Southeast Asia and Pacific region, revenue increased due to the addition of products purchased from other manufacturers for resale following the consolidation of Singapore-based distributor SciMed as a subsidiary in July 2020, as well as the successful capture of demand for vaccine storage in each country.」
The company continues to explain the increase in revenue from the addition of products handled through the establishment of SciMed as a subsidiary and the capture of demand for vaccine storage in each country. - FY2022-Q2First statedAnnual report
「In the Southeast Asia and Pacific region, revenue increased significantly due to the addition of sales of products purchased from other manufacturers following the consolidation of Singapore-based distributor SciMed as a subsidiary in July 2020, as well as the successful capture of demand for vaccine storage in each country.」
Through the consolidation of Singapore-based distributor SciMed as a subsidiary, the company is expanding sales of products manufactured by other companies and capturing demand for vaccine storage in each country.